• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.
Source: Neurology and Therapy - August 8, 2023 Category: Neurology Source Type: research

Neutrophil ‐to‐lymphocyte ratio and its changes predict the 3‐month outcome and mortality in acute ischemic stroke patients after intravenous thrombolysis
ConclusionThe comprehensive report suggests that NLR and its dynamic changes are associated with 3-month outcome and mortality in AIS patients after IVT with good predictive powers.
Source: Brain and Behavior - July 20, 2023 Category: Neurology Authors: Qiong Wu, Hui ‐Sheng Chen Tags: ORIGINAL ARTICLE Source Type: research

The use of alteplase, although safe, does not offer clear clinical advantages when mild stroke is non-disabling
This study aimed to investigate the efficacy and safety of alteplase in patients with mild, non-disabling AIS.MethodsWe included all consecutive patients admitted for AIS at our institution from January 2015 to May 2022 who presented a baseline NIHSS score of 0–5 and fit the criteria to receive intravenous thrombolysis. In order to select only subjects with non-disabling AIS, we excluded patients who scored more than 1 point in the following NIHSS single items: vision, language, neglect, and single limb. Patients who scored at least 1 point in the NIHSS consciousness item were excluded as well. This study is a retrospect...
Source: Frontiers in Neurology - July 17, 2023 Category: Neurology Source Type: research

Evolving Thrombolytics: from Alteplase to Tenecteplase
AbstractAlteplase has been the primary thrombolytic used in the treatment of acute ischemic stroke since thrombolysis was first established as an effective treatment of acute ischemic stroke in 1995. Tenecteplase, a genetically modified tissue plasminogen activator, has gained attention as an attractive alternative to alteplase given its practical workflow advantages and possible superior efficacy in large vessel recanalization. As more data is analyzed both from randomized trials and non-randomized patient registries, there is mounting support that tenecteplase appears to be at least equally, if not more, safe and potenti...
Source: Neurotherapeutics - June 5, 2023 Category: Neurology Source Type: research

Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research

Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke
This cohort study evaluates rates of symptomatic intracranial hemorrhage following stroke with tenecteplase vs alteplase.
Source: JAMA Neurology - May 30, 2023 Category: Neurology Source Type: research

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
ConclusionsStandard-dose alteplase treatment reduced the risk of long-term recurrence of AIS after hospital discharge and the alteplase dose was not associated with the long-term risk of death from AIS.
Source: Neurology and Therapy - May 11, 2023 Category: Neurology Source Type: research

Thrombectomy with or without Bridging Thrombolysis for Anterior Circulation Stroke
Conclusions: In this study, BT seems to yield better clinical and procedural outcomes with lower complication rates than d-MT. These findings may support the additional value of intravenous alteplase in anterior system strokes. Further large-scale, prospective, randomized-controlled studies will clarify the gray lines in this consensus, but this paper is important for reflecting the real-world data in developing countries.
Source: Neurology India - April 29, 2023 Category: Neurology Authors: Leyla Ramazanoglu Mehmet Kocak Isil Kalyoncu Aslan Yilmaz Onal Murat Velioglu Eren Gozke Source Type: research

Thrombectomy with or without Bridging Thrombolysis for Anterior System Stroke
Conclusions: In this study, BT seems to yield better clinical and procedural outcomes with lower complication rates than d-MT. These findings may support the additional value of intravenous alteplase in anterior system strokes. Further large-scale, prospective, randomized-controlled studies will clarify the gray lines in this consensus, but this paper is important for reflecting the real-world data in developing countries.
Source: Neurology India - April 29, 2023 Category: Neurology Authors: Leyla Ramazanoglu Mehmet Kocak Isil Kalyoncu Aslan Yilmaz Onal Murat Velioglu Eren Gozke Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20